Takeda’s Ninlaro Misses Mark In Transplant-Ineligible 1L Myeloma
Executive Summary
Oral proteasome inhibitor fails to reach significance when added to standard combination therapy in first-line myeloma patients who cannot receive marrow transplants, but development continues in other settings.